Search by Drug Name or NDC
NDC 60505-4512-03 Gefitinib 250 mg/1 Details
Gefitinib 250 mg/1
Gefitinib is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Apotex Corp.. The primary component is GEFITINIB.
MedlinePlus Drug Summary
Gefitinib is used to treat non-small cell lung cancer that has spread to other parts of the body in people with certain types of tumors. Gefitinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.
Related Packages: 60505-4512-03Last Updated: 04/28/2024
MedLinePlus Full Drug Details: Gefitinib
Product Information
| NDC | 60505-4512 |
|---|---|
| Product ID | 60505-4512_5fb92c16-3e0f-f445-ede2-9e6db77c6e10 |
| Associated GPIs | |
| GCN Sequence Number | 052086 |
| GCN Sequence Number Description | gefitinib TABLET 250 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 19586 |
| HICL Sequence Number | 025178 |
| HICL Sequence Number Description | GEFITINIB |
| Brand/Generic | Generic |
| Proprietary Name | Gefitinib |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Gefitinib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 250 |
| Active Ingredient Units | mg/1 |
| Substance Name | GEFITINIB |
| Labeler Name | Apotex Corp. |
| Pharmaceutical Class | Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA209532 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 60505-4512-03 (60505451203)
| NDC Package Code | 60505-4512-3 |
|---|---|
| Billing NDC | 60505451203 |
| Package | 30 TABLET in 1 BOTTLE (60505-4512-3) |
| Marketing Start Date | 2023-08-08 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |